Results 61 to 70 of about 68,398 (251)

Research advances of obinutuzumab in the treatment of membranous nephropathy

Linchuang shenzangbing zazhi
Membranous nephropathy （MN） is a common cause of adult nephrotic syndrome. Rituximab, a type Ⅰ anti-CD20 monoclonal antibody, is an effective treatment of MN.
Xiao-jing Lin, Jing Sun, Hao-yi Xiangli, Xuan-yi Du   +3 more
doaj   +1 more source

Two Years of Ocrelizumab Treatment in Black and Hispanic People with Multiple Sclerosis in CHIMES: A Single‐Arm Clinical Trial

Annals of Neurology, EarlyView.
Objective To evaluate the effectiveness and safety of ocrelizumab in self‐identified black and Hispanic people with relapsing multiple sclerosis. Methods The Characterization of Ocrelizumab in Minorities with Multiple Sclerosis (CHIMES) trial, a prospective, open‐label, single‐arm, phase 4 study, intentionally recruited underrepresented populations in ...
Lilyana Amezcua, Anthony T. Reder, Evanthia Bernitsas, Nancy L. Monson, Timothy Vartanian, Gregory F. Wu, Mansoor Saleh, Annette Okai, Ahmed Z. Obeidat, Dilraj Sokhi, Rikisha Parekh, Jinglan Pei, Christopher Harp, David Clayton, Ibraheem Abioye, Mitzi J. Williams, for the CHIMES Study Group   +16 more
wiley   +1 more source

Probing the sensitivity of autoantibody production to B cell depletion by Rituximab [PDF]

, 2010
Rituximab, a monoclonal antibody directed against the human CD20 antigen, causes profound depletion of all B cells. When used in patients with autoimmune disease, IgG autoantibody titres often fall whilst serum IgG anti-tetanus toxoid antibody titres are
Ferraro, Alastair James
core  

Treatment of resistant pemphigus vulgaris with an anti-CD20 monoclonal antibody (Rituximab) [PDF]

, 2003
We describe a 54-year-old man with resistant pemphigus vulgaris. Standard therapies had afforded inadequate control and have been associated with considerable side-effects. The anti-CD20 monoclonal antibody, Rituximab (MabThera, Roche), was trialled with
Cooper, H.L., Healy, E., Friedmann, P.S., Theaker, J.M.   +3 more
core   +1 more source

Severe Late-Onset Neutropenia in a Pregnant Patient with Multiple Sclerosis after Ocrelizumab

Case Reports in Neurology
Introduction: Ocrelizumab is a recombinant humanized anti-CD20 monoclonal antibody used to treat multiple sclerosis. Late-onset neutropenia, absolute neutrophil count <1.5 × 109/L that develops >4 weeks after last drug administration, is
Casey J. Fealko, Morgan N. Rolon-Newton, Marisa J.L. Aitken, Scott D. Gitlin   +3 more
doaj   +1 more source

Single‐Cell Level Characterization of B Cell Depletion and Repopulation Following Rituximab in Systemic Lupus Erythematosus

Arthritis &Rheumatology, EarlyView.
Objective Rituximab, a CD20+ B cell depletion therapy, is frequently used to treat systemic lupus erythematosus (SLE). However, variability in patient response highlights the need for a deeper understanding of the underlying immune cell dynamics of B cell depletion and repopulation.
Haerin Jang, Norzawani Buang, Catherine Sutherland, Wanseon Lee, Lauren Overend, Tarran S. Rupall, Katie L. Burnham, Matthew C. Pickering, Marina Botto, Emma E. Davenport   +9 more
wiley   +1 more source

P7010 Generation of a novel glycosylated anti-CD20 monoclonal antibody in milk of transgenic cattle [PDF]

, 2016
P7010 Generation of a novel glycosylated anti-CD20 monoclonal antibody in milk of transgenic ...
J Wang (20900), N Li (7711346), Bin Tang (13061175), R Zhang (7409630), Y Dai1 (19227733)   +4 more
core  

Expression of an anti-CD33 single-chain antibody by Pichia pastoris [PDF]

, 2005
CD33 is a cell surface glycoprotein expressed on cells of myelomonocytic lineage, leukaemic cells, but not haematopoietic stem cells. By virtue of its expression pattern, CD33 has become a popular target for new immunotherapeutic approaches to treat ...
Nicholls, Peter J., Blower, Philip J., Peter J. Nicholls, Trivett, Amanda J., Blower, P J, Emberson, L M, Philip J. Blower, Nicholls, P J, Amanda J. Trivett, Louise M. Emberson, Emberson, Louise M., Trivett, A J   +11 more
core   +1 more source

BAFF receptor mAb treatment ameliorates development and progression of atherosclerosis in hyperlipidemic ApoE(-/-) mice. [PDF]

PLoS ONE, 2013
AIMS: Option to attenuate atherosclerosis by depleting B2 cells is currently limited to anti-CD20 antibodies which deplete all B-cell subtypes. In the present study we evaluated the capacity of a monoclonal antibody to B cell activating factor-receptor ...
Tin Kyaw, Peng Cui, Christopher Tay, Peter Kanellakis, Hamid Hosseini, Edgar Liu, Antonius G Rolink, Peter Tipping, Alex Bobik, Ban-Hock Toh   +9 more
doaj   +1 more source

Early‐stage health technology assessment of a curative gene therapy for multiple sclerosis

British Journal of Clinical Pharmacology, EarlyView.
Aims Multiple sclerosis (MS) is associated with significant early morbidity, reduced life expectancy and substantial healthcare and societal costs. The primary objective of this study is to assess the early cost‐effectiveness potential of a novel gene therapy, IMMUTOL, for MS compared with current high‐efficacy treatment sequences.
Attila Imre, Balázs Nagy, Rok Hren
wiley   +1 more source